Development of novel therapeutic strategies that target HIF-1

Expert Opinion on Therapeutic Targets

Volumn 10, Issue 2, 2006, Pages 267-280

  Semenza, Gregg L ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hypoxia; Molecular therapeutics; Signal transduction

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 METHOXYESTRADIOL; ANTINEOPLASTIC AGENT; CARBOPLATIN; CELECOXIB; CYCLOOXYGENASE 2; ECHINOMYCIN; ENDOSTATIN; ETOPOSIDE; EVEROLIMUS; FLAVOPIRIDOL; GELDANAMYCIN; GLUCOSE; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; IBUPROFEN; IMATINIB; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NITRIC OXIDE DONOR; NONSTEROID ANTIINFLAMMATORY AGENT; OXYGEN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROLINE DERIVATIVE; RAPAMYCIN; TEMSIROLIMUS; TOPOTECAN; TRASTUZUMAB; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; AUTOCRINE EFFECT; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL; CANCER INHIBITION; CANCER INVASION; CANCER MORTALITY; CANCER RESISTANCE; CELL IMMORTALIZATION; CLINICAL TRIAL; COLORECTAL CANCER; DRUG CHOICE; DRUG MECHANISM; DRUG TARGETING; GENE ACTIVATION; GENE ACTIVITY; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC CODE; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; HYDROXYLATION; HYPOXIA; IMMUNOHISTOCHEMISTRY; MALIGNANT NEOPLASTIC DISEASE; METASTASIS POTENTIAL; MUTATIONAL ANALYSIS; NONHUMAN; ONCOGENE; OXYGEN CONCENTRATION; PROSTATE CANCER; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NEOPLASMS;

EID: 33645786505     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.10.2.267     Document Type: Review

References (166)

1. BELOZEROV VE, VAN MEIR EG: Hypoxia inducible factor-1: a novel target for cancer therapy. Anti-Cancer Drugs (2005) 16:901-909.
2. MAXWELL PH: The HIF pathway in cancer. Semin. Cell. Dev. Biol. (2005) 16:523-530.
3. KAUFMAN B, SCHARF O, ARBEIT J et al.: Proceedings of the oxygen homeostasis/hypoxia meeting. Cancer Res. (2004) 64:3350-3356.
4. POELLINGER L, JOHNSON RS: HIF-1 and hypoxic response: the plot thickens. Curr. Opin. Genet. Dev. (2004) 14:81-85.
5. SEMENZA GL: Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer (2003) 3:721-732.
6. 2 tension. Proc. Natl. Acad. Sci. USA (1995) 92:5510-5514.
7. WANG GL, SEMENZA GL: Purification and characterization of hypoxia-inducible factor 1. J. Biol. Chem. (1995) 270:1230-1237.
8. SEMENZA GL, WANG GL: A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol. Cell. Biol. (1992) 12:5447-5454.
9. SEMENZA GL, JIANG BH, LEUNG SW et al.: Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J. Biol. Chem. (1996) 271:32529-32537.
10. HOGENESCH JB, CHAN WK, JACKIW VH et al.: Characterization of a subset of the basic-helix-loop-helix-PAS superfamily that interacts with components of the dioxin signaling pathway. J. Biol. Chem. (1997) 272:8581-8593.
11. TIAN H, MCKNIGHT SL, RUSSELL DW: Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev. (1997) 11:72-82.
12. O'ROURKE JF, TIAN YM, RATCLIFFE PJ, PUGH CW: Oxygen-regulated and transactivating domains in endothelial PAS protein 1: comparison with hypoxia-inducible factor-1α. J. Biol. Chem. (1999) 274:2060-2071.
13. HU CJ, WANG LY, CHODOSH LA, KEITH B, SIMON MC: Differential roles of hypoxia-inducible factor 1α (HIF-1α) and HIF-2α in hypoxic gene regulation. Mol. Cell. Biol. (2003) 23:9361-9374.
14. RAVAL RR, LAU KW, TRAN MG et al.: Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol. Cell. Biol. (2005) 25:5675-5686.
15. 2 tension. Am. J. Physiol. (1996) 271:C1172-C1180.
16. JEWELL UR, KVIETIKOVA I, SCHEID A, BAUER C, WENGER RH, GASSMANN M: Induction of HIF-1α in response to hypoxia is instantaneous. FASEB J. (2001) 15:1312-1314.
17. JIANG BH, ZHENG JZ, LEUNG SW, ROE R, SEMENZA GL: Transactivation and inhibitory domains of hypoxia-inducible factor 1α: modulation of transcriptional activity by oxygen tension. J. Biol. Chem. (1997) 272:19253-19260.
18. PUGH CW, O'ROURKE JF, NAGAO M, GLEADLE JM, RATCLIFFE PJ: Activation of hypoxia-inducible factor-1: definition of regulatory domains within the α subunit. J. Biol. Chem. (1997) 272:11205-11214.
19. MAXWELL PH, WIESENER MS, CHANG GW et al.: The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature (1999) 399:271-275.
20. 2 sensing. Science (2001) 292:464-468.
21. 2-regulated prolyl hydroxylation. Science (2001) 292:468-472.
22. YU F, WHITE SB, ZHAO Q, LEE FS: HIF-1α binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc. Natl. Acad. Sci. USA (2001) 98:9630-9635.
23. BRUICK RK, MCKNIGHT SL: A conserved family of prolyl-4-hydroxylases that modify HIF. Science (2001) 294:1337-1340.
24. EPSTEIN AC, GLEADLE JM, MCNEILL LA et al.: C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell (2001) 107:43-54.
25. HIRSILA M, KOIVUNEN P, GUNZLER V, KIVIRIKKO KI, MYLLYHARJU J: Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J. Biol. Chem. (2001) 278:30772-30780.
26. EMA M, HIROTA K, MIMURA J et al.: Molecular mechanisms of transcription activation by HLF and HIF-1α in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300. EMBO J. (1999) 18:1905-1914.
27. CARRERO P, OKAMOTO K, COUMAILLEAU P, O'BRIEN S, TANAKA H, POELLINGER L: Redox-regulated recruitment of the transcriptional coactivators CREB-binding protein and SRC-1 to hypoxia-inducible factor 1α. Mol. Cell. Biol. (2000) 20:402-415.
28. RUAS JL, POELLINGER L, PEREIRA T: Functional analysis of hypoxia-inducible factor-1α-mediated transactivation. Identification of amino acid residues critical for transcriptional activation and/or interaction with CREB-binding protein. J. Biol. Chem. (2002) 277:38723-38730.
29. RUAS JL, POELLINGER L, PEREIRA T: Role of CBP in regulating HIF-1-mediated activation of transcription. J. Cell Sci. (2005) 118:301-311.
30. LANDO D, PEET DJ, WHELAN DA, GORMAN JJ, WHITELAW ML: Asparagine hydroxylation of the HIF transactivation domain: a hypoxic switch. Science (2002) 295:858-861.
31. MAHON PC, HIROTA K, SEMENZA GL: FIH-1: a novel protein that interacts with HIF-1α and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. (2001) 15:2675-2686.
32. LANDO D, PEET DJ, GORMAN JJ, WHELAN DA, WHITELAW ML, BRUICK RK: FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. (2002) 16:1466-1471.
33. MCNEILL LA, HEWITSON KS, CLARIDGE TD, SEIBEL JF, HORSFALL LE, SCHOFIELD CJ: Hypoxia-inducible factor asparaginyl hydroxylase (FIH-1) catalyses hydroxylation at the β-carbon of asparagine-803. Biochem. J. (2002) 367:571-575.
34. KOIVUNEN P, HIRSILA M, GUNZLER V, KIVIRIKKO KI, MYLLYHARJU J: Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl-4-hydroxylases. J. Biol. Chem. (2004) 279:9899-9904.
35. VAUPEL P, MAYER A, HOCKEL M: Tumor hypoxia and malignant progression. Methods Enzymol. (2004) 381:335-354.
36. KIM WY, KAELIN WG: Role of VHL gene mutation in human cancer. J. Clin. Oncol. (2004) 22:4991-5004.
37. ZHONG H, DE MARZO AM, LAUGHNER E et al.: Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res. (1999) 59:5830-5835.
38. KRIEG M, HAAS R, BRAUCH H, ACKER T, FLAMME I, PLATE KH: Up-regulation of hypoxia-inducible factors HIF-1α and HIF-2α under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene (2000) 19:5435-5443.
39. ZAGZAG D, ZHONG H, SCALZITTI JM, LAUGHNER E, SIMONS JW, SEMENZA GL: Expression of hypoxia-inducible factor 1α in brain tumors: association with angiogenesis, invasion, and progression. Cancer (2000) 88:2606-2618.
40. ZAGZAG D, KRISHNAMACHARY B, YEE H et al.: Stromal cell-derived factor-1α and CXCR4 expression in hemangioblastoma and dear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor. Cancer Res. (2005) 65:6178-6188.
41. ISAACS JS, JUNG YJ, MOLE DR et al.: HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell (2005) 8:143-153.
42. SELAK MA, ARMOUR SM, MACKENZIE ED et al.: Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase. Cancer Cell (2005) 7:77-85.
43. MANDRIOTA SJ, TURNER KJ, DAVIES DR et al.: HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell (2002) 1:459-468.
44. VLEUGEL MM, GREIJER AE, VAN DER WALL E, VAN DIEST PJ: Mutation analysis of the HIF-1α oxygen-dependent degradation domain in invasive breast cancer. Cancer Genet. Cytogenet. (2005) 163:168-172.
45. LAUGHNER E, TAGHAVI P, CHILES K, MAHON PC, SEMENZA GL: HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell. Biol. (2001) 21:3995-4004.
46. FUKUDA R, HIROTA K, FAN F, JUNG YD, ELLIS LM, SEMENZA GL: Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J. Biol. Chem. (2002) 277:38205-38211.
47. RICHARD DE, BERRA E, POUYSSEGUR J: Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1α in vascular smooth muscle cells. J. Biol. Chem. (2000) 275:26765-26771.
48. PAGE EL, ROBITAILLE GA, POUYSSEGUR J, RICHARD DE: Induction of hypoxia-inducible factor-1α by transcriptional and translational mechanisms. J. Biol. Chem. (2002) 277:48403-48409.
49. HIROTA K, FUKUDA R, TAKABUCHI S et al.: Induction of hypoxia-inducible factor 1 activity by muscarinic acetylcholine receptor signaling. J. Biol. Chem. (2004) 279:41521-41528.
50. KASUNO K, TAKABUCHI S, FUKUDA K et al.: Nitric oxide induces hypoxia-inducible factor 1 activation that is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling. J. Biol. Chem. (2004) 279:2550-2558.
51. METZEN E, ZHOU J, JELKMANN W, FANDREY J, BRUNE B: Nitric oxide impairs normoxic degradation of HIF-1α by inhibition of prolyl hydroxylases. Mol. Cell. Biol. (2003) 14:3470-3481.
52. HAGEN T, TAYLOR CT, LAM F, MONCADA S: Redistribution of intracellular oxygen in hypoxia by nitric oxide: effect on HIF-1α. Science (2003) 302:1975-1978.
53. CALLAPINA M, ZHOU J, SCHNITZER S et al.: Nitric oxide reverses desferrioxamine- and hypoxia-evoked HIF-1α accumulation-implications for prolyl hydroxylase activity and iron. Exp. Cell Res. (2005) 306:274-284.
54. ZHONG H, CHILES K, FELDSER D et al.: Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. (2000) 60:1541-1545.
55. 2 is mediated by hypoxia-inducible factor 1. Cancer Res. (2003) 63:2330-2334.
56. NISHI H, NAKADA T, KYO S, INOUE M, SHAY JW, ISAKA K: Hypoxia-inducible factor 1 mediates upregulation of telomerase (hTERT). Mol. Cell. Biol. (2004) 24:6076-6083.
57. YATABE N, KYO S, MAIDA Y et al.: HIF-1-mediated activation of telomerase in cervical cancer cells. Oncogene (2004) 23:3708-3715.
58. LENGAUER C, KINZLER KW, VOGELSTEIN B: Genetic instabilities in human cancers. Nature (1998) 396:643-649.
59. KOSHIJI M, TO KK, HAMMER S et al.: HIF-1α induces genetic instability by transcriptionally downregulating MutSα expression. Mol Cell (2005) 17:793-803.
60. KELLY BD, HACKETT SF, HIROTA K et al.: Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ. Res. (2003) 93:1074-1081.
61. RAVI R, MOOKERJEE B, BHUJWALLA ZM et al.: Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α. Genes Dev. (2000) 14:34-44.
62. STOELTZING O, MCCARTY MF, WEY JS et al.: Role of hypoxia-inducible factor 1α in gastric cancer cell growth, angiogenesis, and vessel maturation. J. Natl. Cancer Inst. (2004) 96:946-956.
63. MANALO DJ, ROWAN A, LAVOIE T et al.: Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood (2005) 105:659-669.
64. TANG N, WANG L, ESKO J et al.: Loss of HIF-1α in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell (2004) 6:485-495.
65. GATENBY RA, GILLIES RJ: Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer (2004) 4:891-899.
66. 2 homeostasis by hypoxia-inducible factor 1α. Genes Dev. (1998) 12:149-162.
67. ROBEY IF, LIEN AD, WELSH SJ, BAGGETT BK, GILLIES RJ: Hypoxia-inducible factor-1α and the glycolytic phenotype in tumors. Neoplasia (2005) 7:324-330.
68. CRAMER T, YAMANISHI Y, CLAUSEN BE et al.: HIF-1α is essential for myeloid cell-mediated inflammation. Cell (2003) 112:645-657.
69. FELDSER D, AGANI F, IYER NV, PAK B, FERREIRA G, SEMENZA GL: Reciprocal positive regulation of hypoxia-inducible factor 1α and insulin-like growth factor 2. Cancer Res. (1999) 59:3915-3918.
70. GUNARATNAM L, MORLEY M, FRANOVIC A et al.: Hypoxia inducible factor activates the transforming growth factor-α/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells. J. Biol. Chem. (2003) 278:44966-44974.
71. KRISHNAMACHARY B, BERG-DIXON S, KELLY B et al.: Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res. (2003) 63:1138-1143.
72. MCMAHON S, GRONDIN F, MCDONALD PP, RICHARD DE, DUBOIS CM: Hypoxia-enhanced expression of the proprotein convertase furin is mediated by hypoxia-inducible factor-1: impact on the bioactivation of proproteins. J. Biol. Chem. (2005) 280:6561-6569.
73. PETRELLA BL, LOHI J, BRINCKERHOFF CE: Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2α in von Hippel-Lindau renal cell carcinoma. Oncogene (2005) 24:1043-1052.
74. NIIZEKI H, KOBAYASHI M, HORIUCHI I et al.: Hypoxia enhances the expression of autocrine motility factor and the motility of human pancreatic cancer cells. Br. J. Cancer (2002) 86:1914-1919.
75. PENNACCHIETTI S, MICHIELI P, GALLUZZO M, MAZZONE M, GIORDANO S, COMOGLIO PM: Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell (2003) 3:347-361.
76. MULLER A, HOMEY B, SOTO H et al.: Involvement of chemokine receptors in breast cancer metastasis. Nature (2001) 410:50-56.
77. SCHIOPPA T, URANCHIMEG B, SACCANI A et al.: Regulation of the chemokine receptor CXCR4 by hypoxia. J. Exp. Med. (2003) 198:1391-1402.
78. STALLER P, SULITKOVA J, LISZTWAN J, MOCH H, OAKELEY EJ, KREK W: Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature (2003) 425:307-311.
79. AEBERSOLD DM, BURRI P, BEER KT et al.: Expression of hypoxia-inducible factor-1α: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. (2001) 61:2911-2916.
80. UNRUH A, RESSEL A, MOHAMED HG et al.: The hypoxia-inducible factor-1α is a negative factor for tumor therapy. Oncogene (2003) 22:3213-3220.
81. WILLIAMS KJ, TELFER BA, XENAKI D et al.: Enhanced response to radiotherapy in tumors deficient in the function of hypoxia-inducible factor-1. Radiother. Oncol. (2005) 75:89-98.
82. MOELLER BJ, CAO Y, LI CY, DEWHIRST MW: Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell (2004) 5:429-441.
83. COMERFORD KM, WALLACE TJ, KARHAUSEN J, LOUIS NA, MONTALTO MC, COLGAN SP: Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. (2002) 62:3387-3394.
84. KRISHNAMURTHY P, ROSS DD, NAKANISHI T et al.: The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J. Biol. Chem. (2004) 279:24218-24225.
85. MAYERHOFER M, VALENT P, SPERR WR, GRIFFIN JD, SILLABER C: BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1α, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood (2002) 100:3767-3775.
86. IZUMI Y, XU L, DI TOMASO E, FUKUMURA D, JAIN RK: Tumor biology: herceptin acts as an anti-angiogenic cocktail. Nature (2002) 416:279-280.
87. WANG GL, JIANG BH, SEMENZA GL: Effect of protein kinase and phosphatase inhibitors on expression of hypoxia-inducible factor 1. Biochem. Biophys. Res. Commun. (1995) 216:669-675.
88. STEPHENS L, WILLIAMS R, HAWKINS P: Phosphoinositide 3 kinases as drug targets in cancer. Curr. Opin. Pharmacol. (2005) 5:357-365.
89. VOGT PK, BADER AG, KANG S: Phosphoinositide 3-kinase: from viral oncoprotein to drug target. Virology (2006) 344:131-138.
90. KUMAR CC, MADISON V: AKT crystal structure and AKT-specific inhibitors. Oncogene (2005) 24:7493-7501.
91. GUERTIN DA, SABATINI DM: An expanding role for mTOR in cancer. Trends Mol. Med. (2005) 11:353-361.
92. SANSAL I, SELLERS WR: The biology and clinical relevance of the PTEN tumor suppressor pathway. J. Clin. Oncol. (2004) 22:2954-2963.
93. MAJUMDER PK, FEBO PG, BIKOFF R et al.: mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat. Med. (2004) 10:594-601.
94. TSUJII M, KAWANO S, TSUJI S, SAWAOKA H, HORI M, DUBOIS RN: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell (1998) 93:705-716.
95. MASUNAGA R, KOHNO H, DHAR DK et al.: Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin. Cancer Res. (2000) 6:4064-4068.
96. GIARDIELLO FM, HAMILTON SR, KRUSH AJ et al.: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med. (1993) 328:1313-1316.
97. RAO CV, RIVENSON A, SIMI B et al.: Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res. (1995) 55:1464-1472.
98. NECKERS L,: Heat shock protein 90. Curr. Opin. Oncol. (2003) 15:419-424.
99. SOLIT DB, SCHER HI, ROSEN N: Hsp90 as a therapeutic target in prostate cancer. Semin. Oncol. (2003) 30:709-716.
100. GRBOVIC OM, BASSO AD, SAWAI A et al.: V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc. Natl. Acad. Sci. USA (2006) 103:57-62.
101. ISAACS JS, JUNG YJ, MIMNAUGH EG, MARTINEZ A, CUTTITTA F, NECKERS LM: Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1α-degradative pathway. J. Biol. Chem. (2002) 277:29936-29944.
102. KUBO T, MAEZAWA N, OSADA M, KATSUMURA S, FUNAE Y, IMAOKA S: Bisphenol A, an environmental endocrine-disrupting chemical, inhibits hypoxic response via degradation of hypoxia-inducible factor 1α (HIF-1α): structural requirement of bisphenol A for degradation of HIF-1α. Biochem. Biophys. Res. Commun. (2004) 318:1006-1011.
103. NAKAMURA H, NAKAMURA K, YODOI J: Redox regulation of cellular activation. Ann. Rev. Immunol. (1997) 15:351-369.
104. BIAGLOW JE, MILLER RA: The thioredoxin reductase/thioredoxin system: novel redox targets for cancer therapy. Cancer Biol. Ther. (2005) 4:6-13.
105. WELSH SJ, BELLAMY WT, BRIEHL MM, POWIS G: The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1α protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res. (2002) 62:5089-5095.
106. WELSH SJ, WILLIAMS RR, BIRMINGHAM A, NEWMAN DJ, KIRKPATRICK DL, POWIS G: The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1α and vascular endothelial growth factor formation. Mol. Cancer Ther. (2003) 2:235-243.
107. RAPISARDA A, URANCHIMEG B, SCUDIERO DA et al.: Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res. (2002) 62:4316-4324.
108. RAPISARDA A, URANCHIMEG B, SORDET O, POMMIER Y, SHOEMAKER RH, MELILLO G: Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res. (2004) 64:1475-1482.
109. RAPISARDA A, ZALEK J, HOLLINGSHEAD M et al.: Schedule-dependent inhibition of hypoxia-inducible factor-1α protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res. (2004) 64:6845-6848.
110. MABJEESH NJ, ESCUIN D, LAVALLEE TM et al.: 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell (2003) 3:363-375.
111. CHANG H, SHYU KG, LEE CC et al.: GL331 inhibits HIF-1α expression in a lung cancer model. Biochem. Biophys. Res. Commun. (2003) 302:95-100.
112. NELSON DW, CAO H, ZHU Y et al.: A noninvasive approach for assessing tumor hypoxia in xenografts: developing a urinary marker for hypoxia. Cancer Res. (2005) 65:6151-6158.
113. NEWCOMB EW, ALI MA, SCHNEE T et al.: Flavopiridol downregulates hypoxia-mediated hypoxia-inducible factor-1α expression in human glioma cells by a proteasome-independent pathway: implications for in vivo therapy. Neuro-oncol. (2005) 7:225-235.
114. KELLY WK, MARKS PA: Drug insight: histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat. Clin. Pract. Oncol. (2005) 2:150-157.
115. BAYLIN SB: DNA methylation and gene silencing in cancer. Nat. Clin. Pract. Oncol. (2005) 2:S4-S11.
116. JEONG JW, BAE MK, AHN MY et al.: Regulation and destabilization of HIF-1α by ARD1-mediated acetylation. Cell (2002) 111:709-720.
117. BILTON R, MAZURE N, TROTTIER E et al.: Arrest-defective-1 protein, an acetyltransferase, does not alter stability of hypoxia-inducible factor (HIF)-1α and is not induced by hypoxia or HIF. J. Biol. Chem. (2005) 280:31132-31140.
118. DAMES SA, MARTINEZ-YAMOUT M, DE GUZMAN RN, DYSON HJ, WRIGHT PE: Structural basis for HIF-1α/CBP recognition in the cellular hypoxic response. Proc. Natl. Acad. Sci. USA (2002) 99:5271-5276.
119. FREEDMAN SJ, SUN ZY, POY F et al.: Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor 1α. Proc. Natl. Acad. Sci. USA (2002) 99:5367-5372.
120. KUNG AL, ZABLUDOFF SD, FRANCE DS et al.: Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell (2004) 6:33-43.
121. KONG D, PARK EJ, STEPHEN AG et al.: Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res. (2005) 65:9047-9055.
122. KIM JW, ZELLER KI, WANG Y et al.: Evaluation of myc E-box phylogenetic footprints in glycolytic genes by chromatin immunoprecipitation assays. Mol. Cell. Biol. (2004) 24:5923-5936.
123. WELSH S, WILLIAMS R, KIRKPATRICK L, PAINE-MURRIETA G, POWIS G: Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1α. Mol. Cancer Ther. (2004) 3:233-244.
124. YEO EJ, CHUN YS, CHO YS et al.: YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J. Natl. Cancer Inst. (2003) 95:516-525.
125. CHUN YS, YEO EJ, CHOI E et al.: Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochem. Pharmacol. (2001) 61:947-954.
126. NEWMAN DJ, CRAGG GM, SNADER KM: Natural products as sources of new drugs over the period 1981-2002. J. Nat. Prod. (2003) 66:1022-1037.
127. O'HARE T, CORBIN AS, DRUKER BJ: Targeted CML therapy: controlling drug resistance, seeking cure. Curr. Opin. Genet. Dev. (2005) Epub ahead of print.
128. BELL R, VERMA S, UNTCH M, CAMERON D, SMITH I: Maximizing clinical benefit with trastuzumab. Semin. Oncol. (2004) 31(Suppl. 10):35-44.
129. VOGELSTEIN B, KINZLER KW: Cancer genes and the pathways they control. Nat. Med. (2004) 10:789-799.
130. MOELLER BJ, DREHER MR, RABBANI ZN et al.: Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell (2005) 8:99-110.
131. KORKOLOPOULOU P, PATSOURIS E, KONSTANTINIDOU A et al.: Hypoxia-inducible factor 1α/vascular endothelial growth factor axis in astrocytomas: associations with microvessel morphometry, proliferation and prognosis. Neuropathol. Appl. Neurobiol. (2004) 3:267-278.
132. THEODOROPOULOS VE, LAZARIS AC, KASTRIOTIS I et al.: Evaluation of hypoxia-inducible factor 1α overexpression as a predictor of tumor recurrence and progression in superficial urothelial bladder carcinoma. BJU Int. (2005) 95:425-431.
133. THEODOROPOULOS VE, LAZARIS A, SOFRAS F et al.: Hypoxia-inducible factor 1α expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur. Urol. (2004) 46:200-208.
134. GIATROMANOLAKI A, KOUKOURAKIS MI, SIMOPOULOS C et al.: c-erbB-2 related aggressiveness in breast cancer is hypoxia inducible factor-1α dependent. Clin. Cancer Res. (2004) 10:7972-7997.
135. SCHINDL M, SCHOPPMANN SF, SAMONIGG H et al.: Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin. Cancer Res. (2002) 8:1831-1837.
136. BOS R, VAN DER GROEP P, GREIJER AE et al.: Levels of hypoxia-inducible factor-1α independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer (2003) 97:1573-1581.
137. BIRNER P, SCHINDL M, OBERMAIR A, PLANK C, BREITENECKER G, OBERHUBER G: Overexpression of hypoxia-inducible factor 1α is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res. (2000) 60:4693-4696.
138. BURRI P, DJONOV V, AEBERSOLD DM et al.: Significant correlation of hypoxia-inducible factor-1α with treatment outcome in cervical cancer treated with radical radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. (2003) 56:494-501.
139. BACHTIARY B, SCHINDL M, POTTER R et al.: Overexpression of hypoxia-inducible factor 1α indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin. Cancer Res. (2003) 9:2234-2240.
140. SIVRIDIS E, GIATROMANOLAKI A, GATTER KC, HARRIS AL, KOUKOURAKIS MI: Association of hypoxia-inducible factors 1α and 2α with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer (2002) 95:1055-1063.
141. TAKAHASHI R, TANAKA S, HIYAMA T et al.: Hypoxia-inducible factor-1α expression and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncol. Rep. (2003) 10:797-802.
142. GIATROMANOLAKI A, SIVRIDIS E, KOUSKOUKIS C: Hypoxia-inducible factors 1α and 2α are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Res. (2003) 13:493-501.
143. BIRNER P, GATTERBAUER B, OBERHUBER G et al.: Expression of hypoxia-inducible factor-1α in oligodendrogliomas: its impact on prognosis and on neoangiogenesis. Cancer (2001) 92:165-171.
144. BIRNER P, SCHINDL M, OBERMAIR A, BREITENECKER G, OBERHUBER G: Expression of hypoxia-inducible factor 1α in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin. Cancer Res. (2001) 7:1661-1668.
145. KOUKOURAKIS MI, SIMOPOULOS C, POLYCHRONIDIS A et al.: The effect of trastuzumab/docatexel combination on breast cancer angiogenesis: dichotomus effect predictable by the HIF-1α/VEGF pre-treatment status? Anti-Cancer Res. (2003) 23:1673-1680.
146. 2 induces hypoxia-inducible factor-1α stabilization and nuclear localization in a human prostate cancer cell line. J. Biol. Chem. (2002) 277:50081-50086.
147. PALAYOOR ST, TOFILON PJ, COLEMAN CN: Ibuprofen-mediated reduction of hypoxia-inducible factors HIF-1α and HIF-2α in prostate cancer cells. Clin. Cancer Res. (2003) 9:3150-3157.
148. ZHONG H, WILLARD M, SIMONS J: NS398 reduces hypoxia-inducible factor (HIF)-1α and HIF-1 activity: multiple-level effects involving cyclooxygenase-2 dependent and independent mechanisms. Int. J. Cancer (2004) 112:585-595.
149. MABJEESH NJ, POST DE, WILLARD MT et al.: Geldanamycin induces degradation of hypoxia-inducible factor 1α protein via the proteosome pathway in prostate cancer cells. Cancer Res. (2002) 62:2478-2482.
150. HUDSON CC, LIU M, CHIANG GG et al.: Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin. Mol. Cell. Biol. (2002) 22:7004-7014.
151. RICHARD DE, BERRA E, GOTHIE E, ROUX D, POUYSSEGUR J: p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1α (HIF-1α) and enhance the transcriptional activity of HIF-1. J. Biol. Chem. (1999) 274:32631-32637.
152. MINET E, ARNOULD T, MICHEL G et al.: ERK activation upon hypoxia: involvement in HIF-1 activation. FEBS Lett. (2000) 468:53-58.
153. SODHI A, MONTANER S, PATEL V et al.: The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1α. Cancer Res. (2000) 60:4873-4880.
154. HIROTA K, SEMENZA GL: Rac1 activity is required for the activation of hypoxia-inducible factor 1. J. Biol. Chem. (2001) 276:21166-21172.
155. LEE YM, KIM SH, KIM HS et al.: Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1α activity. Biochem. Biophys. Res. Commun. (2003) 300:241-246.
156. SASAKAWA Y, NAOE Y, NOTO T et al.: Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors. Biochem. Pharmacol. (2003) 66:897-906.
157. QIAN DZ, WANG X, KACHHAP SK et al.: The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res. (2004) 64:6626-6634.
158. ABDOLLAHI A, HAHNFELDT P, MAERCKER C et al.: Endostatin's antiangiogenic signaling network. Mol. Cell (2004) 13:649-663.
159. RICKER JL, CHEN Z, YANG XP, PRIBLUDA VS, SWARTZ GM, VAN WAES C: 2-methoxyestradiol inhibits hypoxia-inducible factor 1α, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma. Clin. Cancer Res. (2004) 10:8665-8673.
160. TAN C, DE NORONHA RG, ROECKER AJ et al.: Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res. (2005) 65:1-8.
161. OSADA M, IMAOKA S, FUNAE Y: Apigenin suppresses the expression of VEGF, an important factor for angiogenesis in endothelial cells via degradation of HIF-1α protein. FEBS Lett. (2004) 575:59-63.
162. LIN S, TSAI SC, LEE CC et al.: Berberine inhibits HIF-1α expression via enhanced proteolysis. Mol. Pharmacol. (2004) 66:612-619.
163. MOHAMMED KA, HOSSAIN CF, ZHANG L, BRUICK RK, ZHOU YD, NAGLE DG: Laurenditerpenol, a new diterpene from the tropical marine alga Laurencia intricate that potently inhibits HIF-1-mediated hypoxic signaling in breast tumor cells. J. Nat. Prod. (2004) 67:2002-2007.
164. HOSSAIN CF, KIM YP, BAERSON SR et al.: Saururus cernuus lignans - potent small molecule inhibitors of hypoxia-inducible factor 1. Biochem. Biophys. Res. Commun. (2005) 333:1026-1033.
165. CHAU NM, ROGERS P, AHERNE W et al.: Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible factor-1α induction in response to hypoxic stress and growth factors. Cancer Res. (2005) 65:4918-4828.
166. LI MH, MIAO ZH, TAN WF et al.: Pseudolaric acid B inhibits angiogenesis and reduces hypoxia-inducible factor 1α by promoting proteasome-mediated degradation. Clin. Cancer Res. (2004) 10:8266-8274.